Venus Remedies Launches Infusion FDC Antibiotic, Mebatic

Published: 02-Feb-2010

Venus Remedies has launched Mebatic, an antibiotic combination in infusion form, to cure severe gastro intestinal (GI) infections. Mebatic contains a combination of floroquinolone and nitroimidazole.

It has been identified to be effective on anaerobes, aerobes and protozoa that cause diarrhea, dysentery, enteritis, traveler's diarrhea and acute food poisoning.

Mebatic Infusion has shown 20-25% improved efficacy over the existing therapies. The drug has been developed with a 'chemical vector' that promotes faster recovery and ensures deeper penetration of antibiotic at the site of infection.

Manu Chaudhary, director and head of Venus Medicine Research Center, said: "More effective and innovative therapies are needed as the micro-organism are becoming increasingly resistant to the existing antibiotics like Metronidazole. Due to the increased drug resistance mortality associated with anaerobes in India has gone up to 24-31%, which is indeed a cause of concern.”

The drug has been approved by the Drugs Controller General of India (DCGI) after successful phase II comparative clinical trials conducted by Venus Medicine Research Center, the R&D arm of Venus Remedies.

No items to display

Tell your friend about this article